02.12.2024 13:22:09

Zai Lab, Novocure Report Positive Topline Results From Phase 3 PANOVA-3 Trial Of TTFields Therapy

(RTTNews) - Zai Lab (ZLAB) and Novocure (NVCR) announced that the Phase 3 PANOVA-3 trial met its primary endpoint, showing a statistically significant improvement in median overall survival versus control. PANOVA-3 evaluated the use of Tumor Treating Fields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.

Novocure plans to file for regulatory approval of TTFields in unresectable, locally advanced pancreatic adenocarcinoma based on PANOVA-3. Zai Lab plans to file for regulatory approval in China.

For More Such Health News, visit rttnews.com.

Analysen zu NovoCure Limitedmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

NovoCure Limited 28,50 -2,30% NovoCure Limited
Zai Lab Ltd Unsponsored American Deposit Receipt Repr 1 Sh 25,00 -1,57% Zai Lab Ltd Unsponsored American Deposit Receipt Repr 1 Sh